Publications Database

Aman M. G. et al. (2005)

Acute and long-term safety and tolerability of risperidone in children with autism.

Journal of Child and Adolescent Psychopharmacology

15(6), pp. 869-884

Read Abstract (New Window)

Coskun M. et al. (2009)

Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder.

Journal of Child and Adolescent Psychopharmacology

19(2), pp. :203-206

Read Abstract (New Window)

Gagliano A. et al. (2004)

Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.

Journal of Child and Adolescent Psychopharmacology

14(1), pp. 39-47

Read Abstract (New Window)

Hellings J. A. et al. (2006)

A crossover study of risperidone in children, adolescents and adults with mental retardation.

Journal of Autism and Developmental Disorders

36(3), pp. 401-411

Read Abstract (New Window)

Huang S. , Tsai S. , Yang H. (2010)

Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder.

Chang Gung Medical Journal

33(2), pp. 211-215

Read Abstract (New Window) Read Full (New Window)

Ishitobi M. et al. (2013)

Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.

Clinical Neuropharmacology

September, 36(5), pp. 151-156.

Read Abstract (New Window)

Kemner C. et al. (2002)

Open-label study of olanzapine in children with pervasive developmental disorder.

Journal of Clinical Psychopharmacology

22 pp. 455-460

Read Abstract (New Window)

Malone R. P. et al. (2002)

Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.

Journal of the American Academy of Child and Adolescent Psychiatry

41(2), pp. 140-147

Read Abstract (New Window)

Martin A. et al. (1992)

Open-label quetiapine in the treatment of children and adolescents with autistic disorder.

Journal of Child and Adolescent Psychopharmacology

9(2), pp. 99-107

Read Abstract (New Window)

Masi G. et al. (2003)

A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.

Journal of Clinical Psychiatry

64(9), pp. 1039-1047

Read Abstract (New Window)

McCracken J. T. et al. (2002)

Risperidone in children with autism and serious behavioral problems.

New England Journal of Medicine

347(5), pp. 314-321

Read Abstract (New Window) Read Full (New Window)

Nagaraj R. , Singhi P. , Malhi P. (2006)

Risperidone in children with autism: randomized, placebo-controlled, double-blind study.

Journal of Child Neurology

21(6), pp. 450-455

Read Abstract (New Window)

Posey D. J. et al. (2001)

A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.

Journal of Child and Adolescent Psychopharmacology

11(3), pp. 267-277

Read Abstract (New Window)

Potenza M. et al. (1999)

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

Journal of Clinical Psychopharmacology

19(1), pp. 37-4.

Read Abstract (New Window)

Troost P. et al. (2005)

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.

Journal of the American Academy of Child and Adolescent Psychiatry

44(11), pp. 1137-1144

Read Abstract (New Window)